Legend Biotech Stock: Carvykti Is Sailing High, But Watch The Horizon (NASDAQ:LEGN) - Seeking Alpha

Legend Biotech's (NASDAQ:LEGN) recent financials reveal a dichotomy between robust revenue growth, primarily driven by their CAR-T therapy Carvykti, and ongoing challenges in operational efficiency. The company's financial health is underscored by a substantial increase in collaboration revenue, alongside a commendable improvement in net loss figures. However, escalating administrative and collaboration costs signal potential inefficiencies. Clinically, Carvykti stands as a pivotal asset in Legend Biotech's portfolio, demonstrating significant efficacy in treating multiple myeloma [MM]. Its competitive positioning against rivals like Bristol-Myers Squibb’s (BMY) Abecma and emerging therapies such as Arcellx’s (ACLX) CART-ddBCMA is crucial for its market success. The clinical landscape is dynamic, with Carvykti's expansion into earlier treatment stages and outcomes from ongoing studies like CARTITUDE-4 ...

seekingalpha.com     Nov 21, 2023